Nelson S Yee
Professor, Penn State Hershey Cancer Institute
Nelson S. Yee is a physician-scientist-pharmacist at the Penn State Hershey Cancer Institute, where he is the attending physician of medicine in medical oncology and he specializes in treating patients with cancers of pancreas, liver, biliary tract, esophagus, stomach and intestines. He is director of the Laboratory of Pancreatic Development and Cancer, and his research focuses on the developmental biology and genetics of exocrine pancreas in the zebrafish and translating the developmental regulators of exocrine pancreas into disease biomarkers and therapeutic targets for in pancreatic adenocarcinoma. He is an editorial board member of the Clinical Cancer Drugs, and he is a guest editor of the Current Clinical Pharmacology. He has published original research articles, reviews, case reports, commentaries, and book chapters; and he presented at research conferences in China, Hong Kong, Germany, and America. Dr. Yee received undergraduate education at the Massachusetts College of Pharmacy in Boston, and then pursued medical education and graduate training at the Cornell University Medical College and the Memorial Sloan-Kettering Cancer Center in New York City. He underwent post-graduate clinical training in Internal Medicine and Hematology-Oncology at the Hospital of the University of Pennsylvania in Philadelphia. He was an Instructor in Medicine at the University of Pennsylvania, and then appointed as Assistant Professor of Medicine at the University of Iowa. Currently, Dr. Yee is Assistant Professor of Medicine at the Pennsylvania State University College of Medicine, and he is the course directors of the Clinical Elective in Medical Oncology, Acting Internship in Medical Oncology, and Medicine Clerkship in Medical Oncology.
Nelson S. Yee\'s research program focuses on the developmental biology and genetics of exocrine pancreas in the zebrafish and translating the developmental regulators of exocrine pancreas into clinical biomarkers and molecular targets for personalized therapy in pancreatic adenocarcinoma. To determine the molecular mechanisms underlying development of exocrine pancreas, part of our efforts involve cloning DNA constructs using the technologies such as TALEN and CRISPR to generate transgenic zebrafish with targeted mutations. These transgenic zebrafish will be useful tools for studying the genetic regulation of the developmental events during pancreatic morphogenesis.